PreveCeutical Medical Completes Third Tranche of Private Placement, Secures $200,000 in Funding

Details of Third Tranche Pricing and Unit Composition

On July 27, 2026, PreveCeutical announced the successful closing of its third tranche, issuing 8 million units at a price of $0.025 per unit, resulting in gross proceeds of $200,000. Each unit mirrors the structure of previous tranches, consisting of one common share and one-half of a share purchase warrant.

The warrants grant holders the right to purchase an additional common share at $0.05 per share, exercisable for two years from the closing of the second tranche on June 12, 2026. An acceleration clause allows the company to shorten the warrant expiry if PreveCeutical’s share price trades at or above $0.10 on the Canadian Securities Exchange (or another recognized exchange) for ten consecutive trading days, with a 30-day notice period before warrants expire.

Aggregate Fundraising from Three Tranches

This third tranche is part of PreveCeutical’s ongoing multi-tranche non-brokered private placement. The initial tranche closed on May 12, 2026, issuing 13.6 million units for $340,000, followed by the second tranche on June 12, 2026, with 9.8 million units raising $245,000.

Combined, these three tranches have generated total gross proceeds of $785,000. The company intends to complete further tranches within four weeks of this announcement, though details regarding timing, pricing, and volume remain undisclosed.

Advisory Commission and Finder Compensation for Third Tranche

For the third tranche closing, PreveCeutical paid an advisory commission of $19,600 to one eligible finder and issued 784,000 advisory commission warrants. These warrants are exercisable at $0.05 per share for two years from June 12, 2026, and are subject to the same acceleration provisions as the unit warrants.

Utilization of Third Tranche Proceeds

The company plans to use the $200,000 raised in the third tranche to pay outstanding liabilities, cover operating costs, and provide general working capital. The broader $785,000 raised across all three tranches is intended for these same purposes, although no specific allocation percentages or project details were disclosed.

Overview of PreveCeutical’s Research and Development Initiatives

PreveCeutical describes itself as a health sciences firm focused on developing innovative preventive and curative therapies using organic and nature-identical products. It currently operates five R&D programs: dual gene therapy targeting diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for various treatments; nonaddictive analgesic peptides as alternatives to opioids like morphine and fentanyl; and a therapeutic product for athletes suffering from concussions (mild traumatic brain injury). The announcement did not specify timelines, clinical trial phases, or regulatory progress for these programs.

Securities Hold Period and Regulatory Compliance

All securities issued in the third tranche are subject to a hold period expiring four months and one day after closing on July 27, 2026, in line with Canadian securities regulations. This hold applies to common shares, warrants, and advisory commission warrants, restricting sales or transfers without regulatory exemptions.

PreveCeutical confirmed that these securities have not been and will not be registered under the U.S. Securities Act of 1933, prohibiting their offer or sale in the U.S. absent registration or exemption. The announcement includes a standard disclaimer that it does not constitute an offer to sell or solicitation to buy securities in any jurisdiction where such actions are unlawful.

Trading Listings and Warrant Acceleration Mechanism

PreveCeutical trades on the Canadian Securities Exchange under ticker PREV, on the OTCQB in the U.S. as PRVCF, and on the Frankfurt Securities Exchange as 18H0. The warrant acceleration trigger references the Canadian Securities Exchange price but allows for alternative recognized exchanges if the shares migrate. This multi-exchange listing offers investors trading flexibility across North America and Europe, though liquidity may vary. The announcement did not disclose current trading volumes or market capitalization.

Forward-Looking Statements and Associated Risks

The announcement includes standard forward-looking disclaimers noting that expectations regarding proceeds use and future tranche closings involve risks and uncertainties that may cause actual outcomes to differ materially. Risks include possible changes in proceeds allocation and the potential inability to close further tranches as planned. Investors are directed to PreveCeutical’s filings on SEDAR+ for more risk information. The company disclaims any obligation to update forward-looking statements except as required by law.

Market Outlook and Investor Considerations

The immediate impact on PreveCeutical’s share price was not disclosed. The company’s plan to close additional tranches within four weeks indicates ongoing capital-raising efforts. Investors should monitor announcements regarding timing, pricing, tranche sizes, and updates on the allocation of the $785,000 raised.

The warrant acceleration clause, activated if the share price reaches $0.10 for ten consecutive trading days, represents a potential catalyst for warrant holders. This target is four times the current $0.025 offering price, reflecting the company’s confidence in future valuation growth. Investors are advised to track PreveCeutical’s progress on its five R&D programs, regulatory updates, partnerships, and clinical trials that could influence share price and warrant exercise decisions.